Feedback / Questions
panobinostat (MTX110) - Biodexa Pharma
https://www.globenewswire.com/news-release/2024/02/08/2826009/0/en/Biodexa-Reports-12-Month-Survival-in-MAGIC-G1-Study-of-MTX110-in-Recurrent-Glioblastoma-Patients.html
Feb 8, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next